Cambridge Healthtech Institute's Inaugural

Patient Engagement & Retention

Tech-Enabled, Patient-Centric Approaches to Patient Engagement

May 14-15, 2019


Retention and continued engagement of clinical trial participants is essential to successfully completing a clinical trial on time. With the rise of social media platforms and digital technology, the pharma industry stands to leverage these to improve patient experience, engagement, and adherence. CHI’s Patient Engagement & Retention conference offers case studies and practical solutions on novel, patient-centric and data-driven approaches to patient engagement and retention.

Final Agenda

Tuesday, May 14

10:00 Conference Registration

10:45 PLENARY KEYNOTE SESSION: Enabling Patient-Centric Clinical Trials

10:45 Chairperson Remarks: Patient-Centric Trials: How to Engage the Patients in a Clinical Study

Basker Gummadi, IT Strategy & Digital Transformation, Digital Innovation, Bayer U.S. LLC

Basker will share the results of the patients’ interaction and what is important to them and what keeps them engaged in a trial. He will also share his personal vision of how Digital technologies can help in this space.

10:55 KEYNOTE PRESENTATION: Patient-Centric Trials: Moving from What’s the Matter with Patients to What Matters to Patients

Lisa Shipley, Vice President, Global Digital Analytics, Merck

The overall percentage of potential patients that participate in clinical trial is very low. Engaging patients and removing barriers to patient participation in clinical trials is critically important to the development of new therapies to improve human health. Digital technologies are poised to improve patient participation and experience and shift from a site-centric to a patient-centric model. Pharmaceutical companies and CRO’s are exploring a number of different paradigms deploying technologies such as, telemedicine, wearables, and home-sampling.

11:15 KEYNOTE PANEL DISCUSSION: Going Virtual – Moving towards Patient-Centric, Site-Less Trials

Lisa Shipley, Vice President, Global Digital Analytics, Merck


Linnea Olson, Lung Cancer Patient Advocate


Laura Whitmore, Director, R&D Innovation, Corporate Projects, Otsuka


Basker Gummadi, IT Strategy & Digital Transformation, Digital Innovation, Bayer U.S. LLC


With the rise and integration of new technologies into clinical trials – mHealth, wearables, sensors, the internet of things – there is an unprecedented opportunity for revolutionizing how the industry performs clinical trials. New technology can help move clinical trials from sites directly into patient homes.

  • Virtual trials, decentralized trials, remote trials, site-less trials: What are we all talking about?
  • What are the latest successes and failures?
  • What are the barriers and challenges? How is the industry leveraging technology to make this a reality?
  • What are patients saying about their experience with virtual trials?
  • What does this mean for the future of clinical trials?

11:50 Keynote Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

12:35 pm Dessert Break in the Exhibit Hall


1:45 Chairperson’s Remarks

1:50 Revitalizing Patient Experience in Clinical Research - How Data and Technology Can Help Reimagine Patients as Partners in Clinical Research?

Kamaljit Behera, MBA, Industry Analyst, Transformational Health, Frost & Sullivan

Digital health solutions are increasingly becoming a cornerstone driving the Patient Engagement moment in the overall healthcare space. More particularly, this cultural shift in patient attitude and the pervasive adoption of digital solutions such as smartphones, wearables, and social media are dramatically reshaping the clinical trial industry, demanding sponsors and researchers to view patients as partners in clinical research. As part of this interacting presentation, Frost & Sullivan though leader will provide an unbiased prospective on how the clinical trial industry can leverage digital means to rejuvenate patient engagement and retention strategy: 1., What are the challenges with current clinical trial patient engagement and how these can be filled by emerging digital health solutions? 2., How are these technologies being applied to patient engagement? - Select industry best practices and case studies. 3., Envisioning the Clinical Trial future with Connected Health Ecosystem 4., Strategic imperatives for future success (Analyst prospective for key stakeholders in this space).

2:20 Adding Patient Experience to the Label- Setting Up for Success!

Michelle Shogren, Head of Innovation in Portfolio and Operations, Pharma Development, Bayer

Wondering how you can leverage the technology and newly available data you’re collecting from clinical trials? Find out how patient experience can now be added to the label and set you apart from the rest.

Sanguine_Biosciences 2:50 Presentation to be Announced

3:20 Refreshment Break in the Exhibit Hall

4:05 HealthCaring Conversations for Clinical ResearchSM: A Science-Based Framework for Patient-Centered Conversations

Suzann Johnson, Associate Director, Investigator and Patient Engagement Projects, Global Clinical Development Operations, Janssen R&D

In the increasingly complex clinical research environment, patients are looking for clarity, and a more personal connection with clinical site staff. Site staff are recognizing how complex communicating with patients can be, even for experienced health care providers. In response, Janssen developed HealthCaring Conversations for Clinical Research, an evidence-based framework for facilitating patient-centered conversations. The aim is to help Study Coordinators Understand, Connect and Empower each patient with the ultimate goal of improving the clinical trial experience for both patients and professionals.

Patient Advocacy and Reaching Difficult-to-Recruit Patient Populations

4:35 Partnering with Rare Disease Patient Communities

Kim Mooney, MS, CGC, Associate Director, Patient Advocacy, Ultragenyx

Patient focused drug development requires collaboration, input & accountability from all stakeholders, including Pharma, Healthcare Providers (HCPs) and Patient Advocacy Groups (PAGs). To be successful, this requires us to challenge traditional Pharma thinking & preconceptions, as well as defining compliant roles and responsibilities for interacting with HCPs and PAGs. Additionally, new approaches on how to find, recruit & engage patients (including small, disadvantaged, or lost to follow-up populations) on a long-term basis, throughout the drug development process, will be also presented.

5:05 Session Break

5:30 Start-Up Showcase and Networking Reception

As a part of the Clinical Trial Innovation Summit, attendees are welcome to attend Tuesday night’s Start-Up Showcase and Networking Reception. As technological advances rapidly enter the market, it may become a challenge to keep up and ensure that your organization is effectively leveraging these technologies for improved clinical trial efficiency. Come listen to and network with new, emerging companies in the digital tech space as they provide brief descriptions of their companies and their services or products. Over cocktails in our open reception, connect with emerging products and service providers in the clinical trial space with special focus on the wearable and digital tech space.

7:30 Close of Day

Wednesday, May 15

8:30 Interactive Breakout Discussion Groups with Continental Breakfast

Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become an active part of the discussion at hand. To get the most out of this interactive session and format please come prepared to share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea sharing.

9:25 Session Break

Patient Advocacy and Reaching Difficult-to-Recruit Patient Populations CONT.

9:40 Chairperson’s Remarks

9:45 Panel Discussion: Diversity & Inclusion in Clinical Trials

Cassandra Smith, MBA, Associate Director, Investigator and Patient Engagement, Janssen

Kim Mooney, MS, CGC, Associate Director, Patient Advocacy, Ultragenyx

Anne Marie Inglis, PhD, Senior Director, Global In Country Clinical Operations, GSK

Despite pharma’s best efforts, there is still a disconnect between the makeup of the trial population compared to those affected by the disease. This discussion will address:

  • What are the barriers to increasing diversity in clinical trials?
  • How can pharma, academia/physicians, and advocacy groups collaborate to eliminate disparities in clinical trials?
  • How can the industry leverage new tech and data approaches to increase diversity in patient recruitment?

10:45 Sponsored Presentation (Opportunity Available)

11:00 Coffee Break

Digital Approaches to Clinical Trial Awareness & Patient Engagement

11:30 Digital Approaches for Optimizing Participant Retention and Compliance

Maya Hardigan, Director, Clinical Innovation & mClinical Platform Lead, Pfizer

The proliferation of smart phones and tablets has created new opportunities for robustly engaging clinical trial participants. Pfizer’s mClinical platform serves as an incubation space for patient-facing mobile and digital clinical trial innovations: eConsent, mobile apps supporting protocol compliance, and flexible patient data capture models. This talk will showcase the mClinical Patient Journey and the suite of mobile and digital solutions offered to improve the experience of those participating in Pfizer’s clinical trials.

12:00 A Model for Defining and Measuring User Engagement in Digital Behavior Change Interventions

Nnamdi Ezeanochie, MD, DrPH, Senior Manager, Behavior Science, Johnson & Johnson

Researchers and practitioners of Digital Behavior Change Interventions (DBCIs) use varying and oftentimes incongruent definitions of the term engagement; thus, leading to lack of precision in DBCI measurement and evaluation. The objective of this presentation is to propose nuanced definitions for various types of user engagement and explain why precision in the measurement of these engagement types is integral to ensuring intervention effectiveness. Additionally, this presentation will describe a framework and practical steps for how engagement can be measured in practice and used to inform DBCI design and evaluation especially in the context of clinical trials.

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:15 Session Break

Digital Approaches to Clinical Trial Awareness & Patient Engagement

2:15 Chairperson’s Remarks

2:20 Talk Title to be Announced

Arian Khoshchin, MSc, Head of Digital Health Technologies, ProQR Therapeutics

2:50 Panel Discussion: Digital Strategies for Patient Engagement & Recruitment

Jiao Song, Associate Director, Janssen Clinical Innovation

Dennis Salotti, COO, The Avoca Group

Maya Hardigan, Director, Clinical Innovation & mClinical Platform Lead, Pfizer

Digital advances have made it easier for patients to find information about clinical trials online. How is pharma engaging with this digital audience and how is the industry integrating digital solutions into their clinical trial recruitment strategies? This discussion will address:

  • How is pharma engaging patient and caregiver communities to enhance trial awareness and recruitment?
  • How should pharma leverage social media for patient engagement and clinical trial recruitment? Are some social media platforms better than others (ex. Facebook, Instagram, Twitter, etc.)?
  • What digital strategies (mobile apps, gamification, etc.) should pharma focus on to enhance and accelerate trial recruitment?

3:50 Close of Conference. Arrive early to attend Patient Engagement & Retention


Lee Yuan
(+1) 781-972-5404


(Companies A-O)
Ilana Quigley

(+1) 781-972-5457

(Companies P-Z)
Patty Rose
(+1) 781-972-1349


James Prudhomme
(+1) 781-972-5486